JP2016513458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513458A5 JP2016513458A5 JP2016501065A JP2016501065A JP2016513458A5 JP 2016513458 A5 JP2016513458 A5 JP 2016513458A5 JP 2016501065 A JP2016501065 A JP 2016501065A JP 2016501065 A JP2016501065 A JP 2016501065A JP 2016513458 A5 JP2016513458 A5 JP 2016513458A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer
- tmz
- tumor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 19
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 14
- 229960004964 temozolomide Drugs 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- -1 methyl guanine Chemical compound 0.000 claims 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100025873 RNA-binding protein 27 Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 238000011331 genomic analysis Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775668P | 2013-03-10 | 2013-03-10 | |
| US61/775,668 | 2013-03-10 | ||
| PCT/US2014/022786 WO2014164554A1 (en) | 2013-03-10 | 2014-03-10 | Chemotherapy-resistant immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513458A JP2016513458A (ja) | 2016-05-16 |
| JP2016513458A5 true JP2016513458A5 (enExample) | 2017-04-06 |
Family
ID=50639912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501065A Pending JP2016513458A (ja) | 2013-03-10 | 2014-03-10 | 化学療法耐性免疫細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160024175A1 (enExample) |
| EP (1) | EP2968601A1 (enExample) |
| JP (1) | JP2016513458A (enExample) |
| HK (1) | HK1220614A1 (enExample) |
| WO (1) | WO2014164554A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011053750A2 (en) | 2009-11-02 | 2011-05-05 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| US9511092B2 (en) | 2013-01-28 | 2016-12-06 | St. Jude Children's Research Hospital, Inc. | Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease |
| KR102452767B1 (ko) | 2013-05-14 | 2022-10-12 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 가공된 키메라 항원 수용체 (ｃａｒ) ｔ-세포의 인간 적용 |
| EP3004168A4 (en) | 2013-05-24 | 2017-03-01 | Board of Regents, The University of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| EP3074025A1 (en) * | 2013-11-27 | 2016-10-05 | Baylor College Of Medicine | Csgp4-specific chimeric antigen receptor for cancer |
| EP3105335B1 (en) | 2014-02-14 | 2019-10-02 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors and methods of making |
| KR20210014210A (ko) | 2014-05-15 | 2021-02-08 | 내셔널 유니버시티 오브 싱가포르 | 변형된 천연 살해 세포 및 그의 용도 |
| US9777061B2 (en) | 2014-07-21 | 2017-10-03 | Novartis Ag | Treatment of cancer using a CD33 chimeric antigen receptor |
| KR102612313B1 (ko) | 2014-07-21 | 2023-12-12 | 노파르티스 아게 | 인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료 |
| US10570186B2 (en) | 2014-11-05 | 2020-02-25 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (CAR) to selectively target protein complexes |
| SG10202103475XA (en) * | 2014-12-02 | 2021-05-28 | Prospect Chartercare Rwmc Llc | Methods and compositons for treating cancer |
| CA2972806A1 (en) * | 2014-12-31 | 2016-07-07 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| AR103442A1 (es) | 2015-01-16 | 2017-05-10 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos de ror1 |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| CN107530376A (zh) | 2015-02-18 | 2018-01-02 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| JP6803339B2 (ja) | 2015-04-21 | 2020-12-23 | エンリヴェックス セラピューティクス リミテッド | 治療用のプールされた血液アポトーシス細胞調製物及びそれらの使用 |
| EP4295914A3 (en) | 2015-09-03 | 2024-04-10 | The UAB Research Foundation | Genetically-engineered drug resistant t cells and methods of using the same |
| CA3012827A1 (en) | 2016-02-02 | 2017-08-10 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| CN109069539A (zh) | 2016-02-18 | 2018-12-21 | 恩立夫克治疗有限责任公司 | 用于癌症治疗的联合免疫疗法和细胞因子控制疗法 |
| AU2017313828B2 (en) * | 2016-08-18 | 2019-12-05 | IN8bio, Inc. | Compositions and methods for cancer immunotherapy |
| CN110352197B (zh) * | 2016-12-09 | 2024-02-02 | Uab研究基金会 | 嵌合氯毒素受体 |
| CN106908931B (zh) * | 2016-12-30 | 2019-09-17 | 玉晶光电(厦门)有限公司 | 光学成像镜头 |
| BR112019020001A2 (pt) | 2017-03-27 | 2020-04-28 | Nat Univ Singapore | linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais |
| IL269553B2 (en) | 2017-03-27 | 2025-10-01 | Nat Univ Singapore | Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| JP7360174B2 (ja) | 2018-02-09 | 2023-10-12 | ナショナル ユニヴァーシティー オブ シンガポール | ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用 |
| JP7334985B2 (ja) | 2018-04-02 | 2023-08-29 | ナショナル ユニヴァーシティー オブ シンガポール | 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和 |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CA3100724A1 (en) | 2018-06-13 | 2019-12-19 | Novartis Ag | B-cell maturation antigen protein (bcma) chimeric antigen receptors and uses thereof |
| AU2019330347B2 (en) | 2018-08-29 | 2025-07-24 | National University Of Singapore | A method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| EP4416292A2 (en) | 2021-10-14 | 2024-08-21 | Arsenal Biosciences, Inc. | Immune cells having co-expressed shrnas and logic gate systems |
| EP4615485A1 (en) * | 2022-11-07 | 2025-09-17 | NeoImmuneTech, Inc. | Methods of treating a tumor with an unmethylated mgmt promoter |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
-
2014
- 2014-03-10 HK HK16108665.9A patent/HK1220614A1/zh unknown
- 2014-03-10 JP JP2016501065A patent/JP2016513458A/ja active Pending
- 2014-03-10 WO PCT/US2014/022786 patent/WO2014164554A1/en not_active Ceased
- 2014-03-10 EP EP14721581.8A patent/EP2968601A1/en not_active Ceased
- 2014-03-10 US US14/773,416 patent/US20160024175A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513458A5 (enExample) | ||
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Zhou et al. | Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance | |
| JP6867347B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| JP2016520302A5 (enExample) | ||
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| JP2019517788A5 (enExample) | ||
| Huang et al. | IGF1R-and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas | |
| Helmy et al. | Cancer immunotherapy: accomplishments to date and future promise | |
| Fiorenza et al. | CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success: S. Fiorenza, CJ Turtle | |
| JP2017503472A5 (enExample) | ||
| JP2022025110A (ja) | 操作されたｔ細胞を用いて癌を処置するための方法 | |
| JP2015535689A5 (enExample) | ||
| IL276554B1 (en) | Non-hla restricted t cell receptors and uses thereof | |
| JP2019532997A5 (enExample) | ||
| Guo et al. | Chimeric antigen receptor‐modified T cells for solid tumors: challenges and prospects | |
| JP2021521818A (ja) | 有効な免疫療法のための抗原−サイトカイン複合体に用いた免疫エフェクター細胞及び分子アダプター | |
| RU2015116901A (ru) | Композиции и способы для имуннотерапии | |
| JP2017536812A5 (enExample) | ||
| JP2014512183A5 (enExample) | ||
| JP2020511462A5 (enExample) | ||
| Azadi et al. | Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines | |
| JP2018537536A5 (enExample) | ||
| JP2018526453A5 (enExample) | ||
| Inderberg et al. | Long-term surviving cancer patients as a source of therapeutic TCR |